SEC Comment Letter 0000000000-24-001012 to MADRIGAL PHARMACEUTICALS, INC. (MDGL) (CIK 0001157601) (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) (CIK 0001157601)
Date: Jan. 25, 2024 · CIK: 0001157601 · Accession: 0000000000-24-001012
AI Filing Summary & Sentiment
File numbers found in text: 001-33277
Letter
United States securities and exchange commission logo January 25, 2024 Alex G. Howarth Chief Financial Officer Madrigal Pharmaceuticals, Inc. Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 Re:Madrigal Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 File No. 001-33277 Dear Alex G. Howarth: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 25, 2024
Alex G. Howarth
Chief Financial Officer
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
200 Barr Harbor Drive, Suite 200
West Conshohocken, PA 19428
Re:Madrigal Pharmaceuticals, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
File No. 001-33277
Dear Alex G. Howarth:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences